GRIN1 (Ab-896) Antibody

What is GRIN1 (Ab-896) Antibody and what epitope does it recognize?

GRIN1 (Ab-896) Antibody is a polyclonal antibody that specifically recognizes the phosphorylated serine residue at position 896 (pSer896) in the NMDA receptor subunit 1 (NMDAR1/GRIN1). The antibody is designed to detect the peptide sequence around amino acids 894-898 (R-R-S-S-K) of the NMDAR1 protein . This site-specific phosphorylation is critical for regulating NMDA receptor function in neuronal signaling.

What species reactivity has been validated for GRIN1 (Ab-896) Antibody?

The GRIN1 (Ab-896) Antibody has been validated for reactivity with human, mouse, and rat samples . This cross-species reactivity makes it valuable for comparative studies across different model organisms in neuroscience research.

What are the primary research applications for GRIN1 (Ab-896) Antibody?

The primary validated applications for this antibody include:

• Western Blotting (WB): Recommended dilution 1:500-1:1000

• Enzyme-Linked Immunosorbent Assay (ELISA)

The antibody has been specifically tested and validated in these applications for detecting phosphorylated GRIN1 at Ser896 .

How should I optimize Western blot protocols when using GRIN1 (Ab-896) Antibody?

For optimal Western blot results with GRIN1 (Ab-896) Antibody:

• Sample preparation:

  • Use fresh brain tissue samples when possible

  • Include phosphatase inhibitors in lysis buffers to preserve phosphorylation states

  • Maintain cold temperatures throughout sample processing

• Gel electrophoresis and transfer:

  • The expected molecular weight for NMDAR1/GRIN1 is approximately 105-120 kDa

  • Use 7-10% polyacrylamide gels for optimal separation

• Antibody incubation:

  • Start with 1:500 dilution for initial optimization

  • Incubate in 5% BSA in TBST rather than milk (phospho-epitopes can be masked by milk proteins)

  • Optimal incubation is typically overnight at 4°C

• Positive controls:

  • Mouse or rat brain tissue lysates serve as reliable positive controls

What factors can affect GRIN1 phosphorylation at Ser896 that might impact antibody detection?

Several factors can influence the phosphorylation state at Ser896 and consequently affect antibody detection:

• Protein Kinase C (PKC) activation: Ser896 is primarily phosphorylated by PKC, so treatments that activate or inhibit PKC will affect detection levels

• Neuronal activity: Increased neuronal activity typically enhances Ser896 phosphorylation through glutamatergic signaling

• Sample handling:

  • Postmortem interval in tissue samples

  • Phosphatase activity during sample preparation

  • Freeze-thaw cycles that degrade phospho-epitopes

• Pharmacological treatments:

  • NMDA receptor agonists/antagonists

  • PKC activators/inhibitors

Researchers should carefully control these variables and include appropriate positive and negative controls when designing experiments.

Why might I experience high background or non-specific binding when using GRIN1 (Ab-896) Antibody?

High background or non-specific binding can result from several factors:

• Antibody concentration: Using too high a concentration of primary antibody. Try further dilutions (1:1000-1:2000) to optimize signal-to-noise ratio.

• Blocking conditions: Insufficient blocking can lead to non-specific binding. Use 5% BSA in TBST for 1-2 hours at room temperature.

• Wash steps: Inadequate washing between steps. Increase the number and duration of washes with TBST.

• Cross-reactivity: The antibody might cross-react with other phosphorylated proteins. Verify specificity with:

  • Peptide competition assays

  • Phosphatase treatment controls

  • GRIN1 knockout samples when available

• Sample quality: Degraded samples may show increased non-specific binding. Always use fresh samples with appropriate protease and phosphatase inhibitors.

How can I validate the specificity of GRIN1 (Ab-896) Antibody in my experimental system?

To validate antibody specificity:

• Peptide competition assay:

  • Pre-incubate the antibody with excess phosphorylated peptide (pSer896)

  • Compare with non-phosphorylated peptide pre-incubation

  • Specific signal should decrease only with phospho-peptide competition

• Phosphatase treatment:

  • Treat half of your sample with lambda phosphatase

  • The signal should decrease or disappear in treated samples

• Genetic models:

  • Use GRIN1 knockout or knockdown models as negative controls

  • Use samples with known GRIN1 Ser896 phosphorylation states

• Cross-validation:

  • Compare results with alternative anti-GRIN1 (pSer896) antibodies from different vendors

  • Validate findings using complementary techniques (mass spectrometry, functional assays)

How can GRIN1 (Ab-896) Antibody be used to study NMDA receptor regulation in synaptic plasticity?

GRIN1 (Ab-896) Antibody offers valuable insights into NMDA receptor regulation in synaptic plasticity research:

• Activity-dependent phosphorylation:

  • Monitor Ser896 phosphorylation changes during LTP/LTD induction

  • Compare with other phosphorylation sites (e.g., Ser890) to develop a comprehensive phosphorylation profile

• Subcellular localization studies:

  • Combine with immunofluorescence to track phosphorylated receptor trafficking

  • Use subcellular fractionation to quantify phosphorylated GRIN1 in synaptic vs. extrasynaptic compartments

• Electrophysiology correlation:

  • Correlate Ser896 phosphorylation levels with NMDA receptor current recordings

  • Study how phosphorylation alters channel properties (open probability, conductance)

• Pharmacological manipulations:

  • Assess how NMDAR antagonists/agonists affect Ser896 phosphorylation

  • Study effects of PKC modulators on receptor phosphorylation and function

How can GRIN1 (Ab-896) Antibody be utilized in studies of neurological disorders associated with NMDA receptor dysfunction?

This antibody can be instrumental in studying neurological disorders:

• Neurodevelopmental disorders:

  • Compare Ser896 phosphorylation patterns in GRIN1 mutation models

  • Analyze phosphorylation changes in developmental timeline studies

• Epilepsy models:

  • Monitor Ser896 phosphorylation before, during, and after seizure activity

  • Test potential therapeutic compounds that may normalize phosphorylation

• Neurodegenerative diseases:

  • Study altered NMDA receptor phosphorylation in Alzheimer's or Parkinson's models

  • Correlate with excitotoxicity and cell death markers

• Drug development screening:

  • Use as a readout for compounds that modulate NMDA receptor phosphorylation

  • Integrate with functional assays to correlate phosphorylation with receptor activity

How should phosphorylation changes at Ser896 be quantified and normalized across different experimental conditions?

For accurate quantification and normalization:

• Standard normalization approaches:

  • Normalize phospho-GRIN1 (Ser896) signal to total GRIN1 protein levels

  • Use housekeeping proteins (β-actin, GAPDH) as loading controls

• Advanced normalization strategies:

  • Include phosphorylation-independent epitope antibodies against GRIN1

  • Consider normalization to total protein stain (Ponceau, REVERT)

  • Implement ratiometric analysis of multiple phosphorylation sites

• Statistical considerations:

  • Include biological replicates (n≥3) for statistical power

  • Use appropriate statistical tests based on data distribution

  • Consider paired analysis for before/after treatment comparisons

• Controls for quantification:

  • Include standard curves with known quantities of phosphorylated peptides

  • Use phosphorylation-deficient mutants (S896A) as negative controls

  • Include constitutively phosphorylated samples as positive controls

How do I integrate GRIN1 (Ab-896) Antibody data with functional NMDA receptor assays for comprehensive analysis?

For integrated analysis:

• Correlation with electrophysiology:

  • Pair Western blot data on Ser896 phosphorylation with patch-clamp recordings

  • Correlate phosphorylation levels with changes in NMDA current amplitude, decay kinetics, and Mg²⁺ sensitivity

• Integration with calcium imaging:

  • Combine antibody-based phosphorylation detection with calcium influx measurements

  • Analyze whether Ser896 phosphorylation correlates with altered Ca²⁺ dynamics

• Multi-parameter analysis:

  • Create correlation matrices between phosphorylation levels and multiple functional parameters

  • Implement principal component analysis to identify key variables driving functional changes

• Temporal considerations:

  • Develop time-course analyses correlating phosphorylation changes with functional outcomes

  • Consider both acute and chronic phosphorylation effects on receptor function

How does GRIN1 Ser896 phosphorylation compare with other phosphorylation sites on NMDA receptors?

NMDA receptor function is regulated by multiple phosphorylation sites with distinct properties:

The coordinated phosphorylation at these different sites creates a complex regulatory code that modulates NMDAR function. When designing experiments with GRIN1 (Ab-896) Antibody, researchers should consider:

• The interplay between multiple phosphorylation sites

• Differential regulation by distinct kinases and phosphatases

• Temporal dynamics of phosphorylation/dephosphorylation events

• The potential for hierarchical or sequential phosphorylation

What are the key differences between commercially available antibodies targeting different GRIN1 epitopes?

Different commercial antibodies target distinct GRIN1 epitopes with varying applications:

When selecting an antibody for your research:

• Consider whether you need to detect total GRIN1 or a specific phosphorylated form

• Verify species reactivity for your model system

• Check validation data for your specific application

• Review published literature using the antibody

How can GRIN1 (Ab-896) Antibody be used in combination with genetic manipulation studies?

GRIN1 (Ab-896) Antibody can be effectively paired with genetic approaches:

• CRISPR/Cas9 modification studies:

  • Validate the effects of Ser896 site mutations (S896A or S896E)

  • Monitor phosphorylation changes in cells with edited GRIN1 regulatory genes

• Conditional knockout models:

  • Use with Cre-loxP systems to study cell-type specific effects of GRIN1 deletion

  • Compare phosphorylation patterns before and after gene deletion

• Rescue experiments:

  • Monitor phosphorylation status in GRIN1 knockout cells rescued with wild-type vs. phospho-mutant constructs

  • Use phospho-specific antibody to confirm phosphorylation status of reintroduced constructs

• Transgenic animal models:

  • Verify phosphorylation changes in GRIN1 mutation models associated with neurodevelopmental disorders

  • Study compensatory phosphorylation mechanisms in partial knockout models

The antibody provides a valuable readout for confirming the biochemical consequences of genetic manipulations, establishing clear links between genotype and molecular phenotype.

What considerations are important when using GRIN1 (Ab-896) Antibody for studies across different brain regions or developmental stages?

When extending studies across brain regions or developmental timelines:

• Regional considerations:

  • NMDAR subunit composition varies by brain region, affecting antibody signal interpretation

  • Baseline phosphorylation levels differ between regions (hippocampus vs. cortex vs. cerebellum)

  • Control for region-specific protein expression differences

• Developmental timeline:

  • NMDAR subunit expression and phosphorylation patterns change dramatically during development

  • Ser896 phosphorylation may have different functional consequences at different developmental stages

  • Include age-matched controls for developmental studies

• Methodological adaptations:

  • Optimize tissue processing protocols for different brain regions

  • Adjust antibody concentrations for regions with lower GRIN1 expression

  • Consider longer exposure times for developmental stages with lower expression

• Control selection:

  • Use within-tissue controls when comparing regions

  • Include developmental stage-specific positive controls

  • Consider normalized approaches comparing the ratio of phosphorylated to total GRIN1